Relapsing-remitting


Also found in: Acronyms.

Relapsing-remitting

A pattern of symptoms of multiple sclerosis in which symptomatic attacks occur that last 24 hours or more, followed by complete or almost complete improvement.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
Long-term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 year Results from the SELECTED Extension Study; Gold, R.
Investigating the Relationship Between Cladribine-Mediated Changes in Lymphocyte Counts and Clinical/Magnetic Resonance Imaging Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis: Correlation Analyses from the Double-Blind, 96-week CLARITY Study (poster P02.
The conversion from relapsing-remitting MS to secondary progressive MS occurred faster in current smokers compared with never-smokers but was similar in ex-smokers and never-smokers," the authors said.
launched a phase II placebo-controlled trial involving 250 people with relapsing-remitting MS in 2004.
The objective of this study was to examine perceived cognitive impairment in secondary progressive and relapsing-remitting MS and to examine the relationship between self-reported cognitive symptoms and level of disability, age, and number of years with MS
neurologists and MCO pharmacy directors, decreased risk of sustained disability progression is also one of the greatest unmet needs in relapsing-remitting multiple sclerosis.
This approval for Cladribine Tablets means that people with relapsing-remitting multiple sclerosis in Russia will benefit soon from this effective oral treatment", said Elmar Schnee, President of Merck Serono.
In a two-year study of 148 patients with relapsing-remitting multiple sclerosis (MS), researchers found that those who received monthly intravenous infusions of a substance called immunoglobulin had their symptoms improve, compared with those who received placebo.
neurologists (63 percent) selected Biogen Idec/Elan's Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents.
In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014).
The phase 2 trial involved about 250 people with relapsing-remitting MS in 10 European countries.